Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPhyo Thazin MyintNBNiravkumar BrahmbhattSHSyed A. Hussain

Discussion

Loading...

Member takes

Overview

Meta-analysis shows MRD negativity improves progression-free survival in CLL, highlighting treatment differences across therapies.

Key Points

  • MRD negativity significantly improves progression-free survival in patients treated with chemoimmunotherapy.
  • The analysis included 3,101 patients across 13 studies, focusing on multiple treatment regimens.
  • Systematic review and meta-analysis assessed MRD status and its correlation with progression-free survival.
  • These findings suggest the need to further investigate the role of MRD as a prognostic marker in targeted therapies.

Cite This Study

Myint et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3f3https://doi.org/10.1182/blood-2025-7418
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival2025
  2. 2Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis2025
  3. 3Circulating tumor DNA-based minimal residual disease assessment predicts progression-free survival in diffuse large B-cell lymphoma: A systematic review and meta-analysis2025 · 1 citations
  4. 4Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  5. 5CLL Management: Towards an MRD Guided Therapy2025